Using Tumor Models to Determine Treatments

The purpose of this study is to see if using Patient Derived Organoids (PDO) to choose a drug for the treatment of pancreatic cancer individually for each patient is useful. The study will look at the number of participants who have a response to their assigned drug.

Trial Details

NCT ID

NCT06813079

Phase

PHASE2

Sponsor

University Health Network, Toronto

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Cobimetinib
Ponatinib
Brigatinib
Colchicine
Selinexor
Abemaciclib

Locations (sample)

Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

Age 18 years or over
Ability to understand and willing to sign a written informed consent form in accordance with applicable local and regulatory requirements. Each pat…
Advanced inoperable malignant epithelial pancreatic ductal carcinomas (i.e. primary diagnosis of ductal adenocarcinoma or acinar cell adenocarcinom…
Treatment history meeting one of either:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →